THG heads into its September earnings window with shorts in retreat, analysts nudging targets higher, and the stock trading near a 52-week high — yet insiders have been steady sellers through the rally.
The most striking development in the lending market is how quickly bearish positioning has unwound. Short interest has fallen 35% in a single week to 2.1% of the free float — roughly half the level it held through most of July. The drop happened almost overnight: positions running above 1.1 million shares through early August collapsed to around 750,000 by August 11. Borrow remains essentially uninhibited, with availability at the ceiling of the lending pool and cost to borrow barely above 0.5%, a level that implies no friction whatsoever for anyone still holding a short. The ORTEX short score of 31.5 is consistent with this ease — the score dipped from 35.9 on August 10 to 31.5 now, tracking the same exit. This is an orderly capitulation, not a squeeze.
Options tell a slightly more cautious story, though not an alarming one. The put/call ratio of 1.34 is above its 20-day average of 1.08, but only modestly so — less than half a standard deviation elevated — and the ratio has actually eased from above 1.5 in late July and early August. That prior defensiveness has faded alongside the short exit. The 52-week range on the PCR runs from 0.18 to 13.9, so the current reading lands firmly in the middle of the distribution. Taken together, positioning looks relaxed rather than charged.
The analyst community has followed the stock higher without committing to it. Morgan Stanley raised its target to $240 this morning — maintaining an Equal-Weight — while RBC lifted to $235 after Q2 results in late July, also staying at Sector Perform. Keefe Bruyette moved to $222. Every recent upgrade has come with a neutral-band rating attached. The mean Street target of $236.50 sits roughly 6% above the current price of $222.17, which is a modest implied upside for a name that has already gained 10% in a week and around 4% over the past month. Bulls point to high-single-digit rate increases in 2026 and 2027, improving return on equity into the high teens, and strong net investment income from higher-yield portfolio repositioning. Bears flag loss ratios across accident years 2021–2025 that remain above pre-Covid levels and warn that earnings growth could flatten into 2027. The PE of 11.4x and price-to-book of 1.88x are not stretched, though EV/EBITDA has compressed about half a turn over the past month as the stock moved up. On factor scores, THG ranks in the 80th percentile for EPS surprise and the 86th for dividend — a quality anchor even if the dividend data itself is dated.
Institutional flows add an interesting counter-narrative to the short exit. T. Rowe Price added 233,000 shares through June, and Fuller & Thaler and American Century each added close to 100,000 shares — all before the recent leg higher. That accumulation preceded the August move, suggesting the re-rating was not simply mechanical short covering. Against that backdrop, insider sales stand out: EVP Jeffrey Farber sold $11.5 million worth of shares on July 29 alone, and CEO John Roche liquidated around $1.6 million in May. Net insider selling over the past 90 days totals roughly $27 million. None of these trades carry high significance scores, and sales after a large rally are not unusual, but the pattern is worth noting alongside the institutional buying.
THG reports next on September 17. The last two prints each produced positive one-day moves — 2.7% and 5.8% respectively — so the earnings reaction bar is set on the constructive side. What to watch from here is whether the analyst community, broadly parked in neutral-band ratings despite repeated target increases, finally upgrades the stock on sustained underwriting margin improvement, or whether the bear case on stalling earnings growth reasserts itself as 2027 guidance comes into view.
See the live data behind this article on ORTEX.
Open THG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
